3,116 Shares in The Cooper Companies, Inc. (NASDAQ:COO) Bought by Crestline Management LP

Crestline Management LP bought a new position in The Cooper Companies, Inc. (NASDAQ:COO) in the 4th quarter, Holdings Channel.com reports. The fund bought 3,116 shares of the medical device company’s stock, valued at approximately $286,000.

Several other hedge funds also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Cooper Companies by 517.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,529,477 shares of the medical device company’s stock valued at $324,466,000 after purchasing an additional 2,957,421 shares during the last quarter. Norges Bank bought a new position in shares of Cooper Companies during the 4th quarter valued at about $217,906,000. FMR LLC boosted its holdings in shares of Cooper Companies by 97.6% during the 4th quarter. FMR LLC now owns 2,218,112 shares of the medical device company’s stock valued at $203,911,000 after purchasing an additional 1,095,805 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Cooper Companies during the 4th quarter valued at about $64,826,000. Finally, Victory Capital Management Inc. boosted its holdings in shares of Cooper Companies by 14.6% during the 4th quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock valued at $415,985,000 after purchasing an additional 574,899 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Stock Performance

Cooper Companies stock opened at $82.27 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The Cooper Companies, Inc. has a 1-year low of $69.81 and a 1-year high of $112.38. The firm has a market capitalization of $16.45 billion, a P/E ratio of 42.19, a price-to-earnings-growth ratio of 2.25 and a beta of 1.08. The company’s 50-day moving average is $80.54 and its 200 day moving average is $90.81.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company had revenue of $964.70 million for the quarter, compared to analyst estimates of $981.25 million. Research analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on COO shares. Piper Sandler restated an “overweight” rating and set a $115.00 target price (down from $120.00) on shares of Cooper Companies in a research report on Friday, March 7th. Robert W. Baird decreased their target price on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a research report on Friday, March 7th. Citigroup decreased their target price on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. JPMorgan Chase & Co. decreased their target price on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Finally, BNP Paribas upgraded shares of Cooper Companies to a “hold” rating in a research report on Thursday, March 13th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Cooper Companies presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.25.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.